Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Net Cash Flow (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Net Cash Flow for 2 consecutive years, with -$12.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 1016.12% to -$12.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.0 million through Dec 2025, up 271.44% year-over-year, with the annual reading at $22.0 million for FY2025, 271.44% up from the prior year.
  • Net Cash Flow hit -$12.3 million in Q4 2025 for Prelude Therapeutics, down from $21.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $27.8 million in Q1 2025 to a low of -$16.7 million in Q3 2024.